|
1
|
Pelizzo MR, Dobrinja C, Casal Ide E, Zane
M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J,
et al: The role of BRAF(V600E) mutation as poor prognostic factor
for the outcome of patients with intrathyroid papillary thyroid
carcinoma. Biomed Pharmacother. 68:413–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel
SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised American
Thyroid Association management guidelines for patients with thyroid
nodules and differentiated thyroid cancer. Thyroid. 19:1167–1214.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pacini F, Schlumberger M, Dralle H, Elisei
R, Smit JW and Wiersinga W: European Thyroid Cancer Taskforce:
European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santoro M and Vecchio G: Thyroid cancer: A
molecular perspective. Mol Cell Endocrinol. 321:1–2. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robinson MJ and Cobb MH: Mitogen-activated
protein kinase pathways. Curr Opin Cell Biol. 9:180–186. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pizzolanti G, Russo L, Richiusa P, Bronte
V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M,
et al: Fine-needle aspiration molecular analysis for the diagnosis
of papillary thyroid carcinoma through BRAF V600E mutation and
RET/PTC rearrangement. Thyroid. 17:1109–1115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiosea S, Nikiforova M, Zuo H, Ogilvie J,
Gandhi M, Seethala RR, Ohori NP and Nikiforov Y: A novel complex
BRAF mutation detected in a solid variant of papillary thyroid
carcinoma. Endocr Pathol. 20:122–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santarpia L, Sherman SI, Marabotti A,
Clayman GL and El-Naggar AK: Detection and molecular
characterization of a novel BRAF activated domain mutation in
follicular variant of papillary thyroid carcinoma. Hum Pathol.
40:827–833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Namba H, Nakashima M, Hayashi T, Hayashida
N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and
Yamashita S: Clinical implication of hot spot BRAF mutation, V599E,
in papillary thyroid cancers. J Clin Endocrinol Metab.
88:4393–4397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikiforova MN and Nikiforov YE: Molecular
genetics of thyroid cancer: Implications for diagnosis, treatment
and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Project CG, Jones CM, Marshall CJ,
Springer CJ, et al: Cancer Genome Project: Mechanism of activation
of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vasko V, Espinosa AV, Scouten W, He H,
Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la
Chapelle A, et al: Gene expression and functional evidence of
epithelial-to-mesenchymal transition in papillary thyroid carcinoma
invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nucera C, Lawler J and Parangi S:
BRAF(V600E) and microenvironment in thyroid cancer: A functional
link to drive cancer progression. Cancer Res. 71:2417–2422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schweppe RE, Kerege AA, Sharma V,
Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL and Haugen BR:
Distinct genetic alterations in the mitogen-activated protein
kinase pathway dictate sensitivity of thyroid cancer cells to
mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid.
19:825–835. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang KT and Lee CH: BRAF mutation in
papillary thyroid carcinoma: Pathogenic role and clinical
implications. J Chin Med Assoc. 73:113–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lupi C, Giannini R, Ugolini C, Proietti A,
Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and
Basolo F: Association of BRAF V600E mutation with poor
clinicopathological outcomes in 500 consecutive cases of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim SJ, Lee KE, Myong JP, Park JH, Jeon
YK, Min HS, Park SY, Jung KC, Koo Do H and Youn YK: BRAF V600E
mutation is associated with tumor aggressiveness in papillary
thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Frasca F, Nucera C, Pellegriti G, Gangemi
P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et
al: BRAF(V600E) mutation and the biology of papillary thyroid
cancer. Endocr Relat Cancer. 15:191–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee KC, Li C, Schneider EB, Wang Y,
Somervell H, Krafft M, Umbricht CB and Zeiger MA: Is BRAF mutation
associated with lymph node metastasis in patients with papillary
thyroid cancer? Surgery. 152:977–983. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim TY, Kim WB, Song JY, Rhee YS, Gong G,
Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is
not associated with poor prognostic factors in Korean patients with
conventional papillary thyroid microcarcinoma. Clin Endocrinol
(Oxf). 63:588–593. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu RT, Chen YJ, Chou FF, Li CL, Wu WL,
Tsai PC, Huang CC and Cheng JT: No correlation between BRAFV600E
mutation and clinicopathological features of papillary thyroid
carcinomas in Taiwan. Clin Endocrinol (Oxf). 63:461–466. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pelttari H, Schalin-Jäntti C, Arola J,
Löyttyniemi E, Knuutila S and Välimäki MJ: BRAF V600E mutation does
not predict recurrence after long-term follow-up in TNM stage I or
II papillary thyroid carcinoma patients. APMIS. 120:380–386. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Abdel-Mageed AB and Kandil E: BRAF
mutation in papillary thyroid carcinoma. Int J Clin Exp Med.
5:310–315. 2012.PubMed/NCBI
|
|
31
|
Derdas SP, Soulitzis N, Balis V, Sakorafas
GH and Spandidos DA: Expression analysis of B-Raf oncogene in
V600E-negative benign and malignant tumors of the thyroid gland:
Correlation with late disease onset. Med Oncol. 30:3362013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li F, Chen G, Sheng C, Aaron GM, Huang Y,
Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary
thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer.
22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Durante C, Puxeddu E, Ferretti E, Morisi
R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A,
et al: BRAF mutations in papillary thyroid carcinomas inhibit genes
involved in iodine metabolism. J Clin Endocrinol Metab.
92:2840–2843. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stephen JK, Chitale D, Narra V, Chen KM,
Sawhney R and Worsham MJ: DNA methylation in thyroid tumorigenesis.
Cancers (Basel). 3:1732–1743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shimamura M, Nakahara M, Orim F, Kurashige
T, Mitsutake N, Nakashima M, Kondo S, Yamada M, Taguchi R, Kimura
S, Nagayama Y, et al: Postnatal Expression of BRAFV600E does not
induce thyroid cancer in mouse models of thyroid papillary
carcinoma. Endocrinology. 154:4423–4430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Watanabe R, Hayashi Y, Sassa M, Kikumori
T, Imai T, Kiuchi T and Murata Y: Possible involvement of BRAFV600E
in altered gene expression in papillary thyroid cancer. Endocr J.
56:407–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Melillo RM, Castellone MD, Guarino V, De
Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R,
Kruhoffer M, et al: The RET/PTC-RAS-BRAF linear signaling cascade
mediates the motile and mitogenic phenotype of thyroid cancer
cells. J Clin Invest. 115:1068–1081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mesa C Jr, Mirza M, Mitsutake N, Sartor M,
Medvedovic M, Tomlinson C, Knauf JA, Weber GF and Fagin JA:
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells
is associated with gene expression profiles that predict a
preferential role of BRAF in extracellular matrix remodeling.
Cancer Res. 66:6521–6529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Palona I, Namba H, Mitsutake N, Starenki
D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y,
Umezawa K and Yamashita S: BRAFV600E promotes invasiveness of
thyroid cancer cells through nuclear factor kappaB activation.
Endocrinology. 147:5699–5707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakayama H, Yoshida A, Nakamura Y, Hayashi
H, Miyagi Y, Wada N, Rino Y, Masuda M and Imada T: Clinical
significance of BRAF (V600E) mutation and Ki-67 labeling index in
papillary thyroid carcinomas. Anticancer Res. 27:3645–3649.
2007.PubMed/NCBI
|
|
41
|
Franzoni A, Dima M, D'Agostino M, Puppin
C, Fabbro D, Di Loreto C, Pandolfi M, Puxeddu E, Moretti S, Celano
M, et al: Prohibitin is overexpressed in papillary thyroid
carcinomas bearing the BRAF(V600E) mutation. Thyroid. 19:247–255.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha
SY, Lee HJ, Sul JY, Kweon GR, Ro H, et al: Influence of the BRAF
V600E mutation on expression of vascular endothelial growth factor
in papillary thyroid cancer. J Clin Endocrinol Metab. 91:3667–3670.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giordano TJ, Kuick R, Thomas DG, Misek DE,
Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al:
Molecular classification of papillary thyroid carcinoma: Distinct
BRAF, RAS, and RET/PTC mutation-specific gene expression profiles
discovered by DNA microarray analysis. Oncogene. 24:6646–6656.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu S, Liu D, Tufano RP, Carson KA,
Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ,
Tolaney S, et al: Association of aberrant methylation of tumor
suppressor genes with tumor aggressiveness and BRAF mutation in
papillary thyroid cancer. Int J Cancer. 119:2322–2329. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Porra V, Ferraro-Peyret C, Durand C,
Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix J-L,
Bournaud C, Orgiazzi J, et al: Silencing of the tumor suppressor
gene SLC5A8 is associated with BRAF mutations in classical
papillary thyroid carcinomas. J Clin Endocrinol Metab.
90:3028–3035. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zane M, Agostini M, Enzo MV, Casal Ide E,
Del Bianco P, Torresan F, Merante Boschin I, Pennelli G, Saccani A,
Rubello D, et al: Circulating cell-free DNA, SLC5A8 and SLC26A4
hypermethylation, BRAF(V600E): A non-invasive tool panel for early
detection of thyroid cancer. Biomed Pharmacother. 67:723–730. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu D, Hu S, Hou P, Jiang D, Condouris S
and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores
expression of iodide-metabolizing genes in thyroid cells expressing
the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Puxeddu E, Durante C, Avenia N, Filetti S
and Russo D: Clinical implications of BRAF mutation in thyroid
carcinoma. Trends Endocrinol Metab. 19:138–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Oler G and Cerutti JM: High prevalence of
BRAF mutation in a Brazilian cohort of patients with sporadic
papillary thyroid carcinomas: Correlation with more aggressive
phenotype and decreased expression of iodide-metabolizing genes.
Cancer. 115:972–980. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mian C, Barollo S, Pennelli G, Pavan N,
Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero
F, et al: Molecular characteristics in papillary thyroid cancers
(PTCs) with no 131I uptake. Clin Endocrinol (Oxf). 68:108–116.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Romei C, Ciampi R, Faviana P, Agate L,
Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A
and Elisei R: BRAFV600E mutation, but not RET/PTC rearrangements,
is correlated with a lower expression of both thyroperoxidase and
sodium iodide symporter genes in papillary thyroid cancer. Endocr
Relat Cancer. 15:511–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gómez Sáez JM: Diagnostic and prognostic
markers in differentiated thyroid cancer. Curr Genomics.
12:597–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Baloch ZW, LiVolsi VA, Asa SL, Rosai J,
Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK and Frable WJ:
Diagnostic terminology and morphologic criteria for cytologic
diagnosis of thyroid lesions: A synopsis of the National Cancer
Institute Thyroid Fine-Needle Aspiration State of the Science
Conference. Diagn Cytopathol. 36:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hayes DF, Bast RC, Desch CE, Fritsche H
Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG,
Norton L, et al: Tumor marker utility grading system: A framework
to evaluate clinical utility of tumor markers. J Natl Cancer Inst.
88:1456–1466. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kulasingam V and Diamandis EP: Strategies
for discovering novel cancer biomarkers through utilization of
emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xing M: Gene methylation in thyroid
tumorigenesis. Endocrinology. 148:948–953. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dalle Carbonare L, Frigo A, Francia G,
Davì MV, Donatelli L, Stranieri C, Brazzarola P, Zatelli MC,
Menestrina F and Valenti MT: Runx2 mRNA expression in the tissue,
serum, and circulating non-hematopoietic cells of patients with
thyroid cancer. J Clin Endocrinol Metab. 97:E1249–E1256. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F,
Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA
profiles as potential biomarkers for diagnosis of papillary thyroid
carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Milas M, Shin J, Gupta M, Novosel T, Nasr
C, Brainard J, Mitchell J, Berber E and Siperstein A: Circulating
thyrotropin receptor mRNA as a novel marker of thyroid cancer:
Clinical applications learned from 1758 samples. Ann Surg.
252:643–651. 2010.PubMed/NCBI
|
|
60
|
Haugen BR, Woodmansee WW and McDermott MT:
Towards improving the utility of fine-needle aspiration biopsy for
the diagnosis of thyroid tumors. Clin Endocrinol (Oxf). 56:281–290.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sahin M, Gursoy A, Tutuncu NB and Guvener
DN: Prevalence and prediction of malignancy in cytologically
indeterminate thyroid nodules. Clin Endocrinol (Oxf). 65:514–518.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Letsas KP, Andrikoula M and Tsatsoulis A:
Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid
nodules: A useful preoperative diagnostic tool. Minerva Endocrinol.
31:179–182. 2006.PubMed/NCBI
|
|
63
|
Santoro M, Dathan NA, Berlingieri MT,
Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G and Fusco
A: Molecular characterization of RET/PTC3; a novel rearranged
version of the RETproto-oncogene in a human thyroid papillary
carcinoma. Oncogene. 9:509–516. 1994.PubMed/NCBI
|
|
64
|
Pupilli C, Pinzani P, Salvianti F, Fibbi
B, Rossi M, Petrone L, Perigli G, De Feo ML, Vezzosi V, Pazzagli M,
et al: Circulating BRAFV600E in the diagnosis and follow-up of
differentiated papillary thyroid carcinoma. J Clin Endocrinol
Metab. 98:3359–3365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kebebew E, Weng J, Bauer J, Ranvier G,
Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence
and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.
246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zagzag J, Pollack A, Dultz L, Dhar S,
Ogilvie JB, Heller KS, Deng FM and Patel KN: Clinical utility of
immunohistochemistry for the detection of the BRAF v600e mutation
in papillary thyroid carcinoma. Surgery. 154:1199–1205. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Espinosa AV, Porchia L and Ringel MD:
Targeting BRAF in thyroid cancer. Br J Cancer. 96:16–20. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Henderson YC, Shellenberger TD, Williams
MD, El-Naggar AK, Fredrick MJ, Cieply KM and Clayman GL: High rate
of BRAF and RET/PTC dual mutations associated with recurrent
papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ricarte-Filho JC, Ryder M, Chitale DA,
Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA,
Tuttle RM, et al: Mutational profile of advanced primary and
metastatic radioactive iodine-refractory thyroid cancers reveals
distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res.
69:4885–4893. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hoeflich KP, Herter S, Tien J, Wong L,
Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, et
al: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is
predicted by BRAFV600E mutational status and sustained
extracellular signal-regulated kinase/mitogen-activated protein
kinase pathway suppression. Cancer Res. 69:3042–3051. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Saji M and Ringel MD: The PI3K-Akt-mTOR
pathway in initiation and progression of thyroid tumors. Mol Cell
Endocrinol. 321:20–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–34.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gupta-Abramson V, Troxel AB, Nellore A,
Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT,
Loevner LA, O'Dwyer PJ and Brose MS: Phase II trial of sorafenib in
advanced thyroid cancer. J Clin Oncol. 26:4714–4719. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Smalley KS: PLX-4032, a small-molecule
B-Raf inhibitor for the potential treatment of malignant melanoma.
Curr Opin Investig Drugs. 11:699–706. 2010.PubMed/NCBI
|
|
76
|
Salerno P, De Falco V, Tamburrino A, Nappi
TC, Vecchio G, Schweppe RE, Bollag G, Santoro M and Salvatore G:
Cytostatic activity of adenosine triphosphate-competitive kinase
inhibitors in BRAF mutant thyroid carcinoma cells. J Clin
Endocrinol Metab. 95:450–455. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xing J, Liu R, Xing M and Trink B: The
BRAFT1799A mutation confers sensitivity of thyroid cancer cells to
the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res
Commun. 404:958–962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of
a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci USA. 105:3041–3046. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ball DW, Jin N, Rosen DM, Dackiw A,
Sidransky D, Xing M and Nelkin BD: Selective growth inhibition in
BRAF mutant thyroid cancer by the mitogen-activated protein kinase
kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab.
92:4712–4718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liu D, Liu Z, Jiang D, Dackiw AP and Xing
M: Inhibitory effects of the mitogen-activated protein kinase
kinase inhibitor CI-1040 on the proliferation and tumor growth of
thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol
Metab. 92:4686–4695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Leboeuf R, Baumgartner JE, Benezra M,
Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA and Fagin
JA: BRAFV600E mutation is associated with preferential sensitivity
to mitogen-activated protein kinase kinase inhibition in thyroid
cancer cell lines. J Clin Endocrinol Metab. 93:2194–2201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Liu D and Xing M: Potent inhibition of
thyroid cancer cells by the MEK inhibitor PD0325901 and its
potentiation by suppression of the PI3K and NF-kappaB pathways.
Thyroid. 18:853–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Xing M: Genetic-targeted therapy of
thyroid cancer: A real promise. Thyroid. 19:805–809. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
87
|
Musholt TJ, Schönefeld S, Schwarz CH,
Watzka FM, Musholt PB, Fottner C, Weber MM, Springer E and Schad A:
Impact of pathognomonic genetic alterations on the prognosis of
papillary thyroid carcinoma. ESES vienna presentation. Langenbecks
Arch Surg. 395:877–883. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sullivan RJ and Flaherty KT: Resistance to
BRAF-targeted therapy in melanoma. Eur J Cancer. 49:1297–1304.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Guerra A, Sapio MR, Marotta V, Campanile
E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G and
Vitale M: The primary occurrence of BRAF(V600E) is a rare clonal
event in papillary thyroid carcinoma. J Clin Endocrinol Metab.
97:517–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Corcoran RB, Ebi H, Turke AB, Coffee EM,
Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D,
Hung KE, et al: EGFR-mediated re-activation of MAPK signaling
contributes to insensitivity of BRAF mutant colorectal cancers to
RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Prahallad A, Sun C, Huang S, Di
Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A
and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature.
483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–703. 2012. View Article : Google Scholar : PubMed/NCBI
|
